Immuno-Oncology's Biomarker Dilemma How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Spring 2017
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated.
Breath based biomarker detection - informing drug development and future treatment regimes By Billy Boyle and Dr Mike Murphy Fall 16
The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes.
Individualised Systems Medicine next-generation precision cancer medicine and drug positioning. By Tea Pemovska, Paaivi Ãstling, Caroline Heckman, Olli Kallioniemi and Krister Wennerberg Summer 15
A growing number of oncology drugs are currently clinically available and more than a thousand compounds are being developed for oncology indications.
Automating the drive towards Personalised Medicine. By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Summer 2014
Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether â and how â a patientâs gene expression profile has changed, as well as the rate of disease progression.
Could the keys to precision and personalised medicine be rooted in predictive safety and research methods? By Robert G. Hunter Spring 2014
To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care.
Biomarker discovery: the need for new generation peptideprotein microarrays. By Dr Nikolai Schwabe and Katherine Catchpole Fall 2013
The progression from health to disease is marked by significant biological changes within an individual1. Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after a disease has already become well-established and consequently more difficult to treat.
Laboratory automation advances high throughput bio-inspired research into personalised medicine. By Dr Joshua LaBaer Summer 2013
The Biodesign Institute at Arizona State University plays an important role in addressing global healthcare challenges by developing bio-inspired solutions that can be translated into commercially viable products and clinical practices. With 11 different research centres, ranging from environmental biotechnology to infectious diseases and vaccinology, and evolutionary medicine and informatics to personalised diagnostics, the Institute is ideally positioned to capitalise on an extensive range of skills and capabilities to resolve complex issues affecting human health and the environment.
Metabolomics: analytic methods driving exponential understanding. By Dr Ian D. Jardine Fall 2012
Metabolomics is distinct from genomics and proteomics in several significant respects. Where genes and proteins are unique to specific organisms, metabolites are ubiquitous throughout the plant and animal kingdoms. Compared with proteomics and genomics, which quantify the building blocks and machinery of organisms, metabolomics provides information about the interaction between the more established âomics and what has been termed as the âwild cardâ of systems biology â the organismâs environment.
Collaborative research leads to new understanding of Biomarkers. By Dr Max Ryadnov and Professor Jason Crain Spring 2012
A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related âbiomarkersâ â in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable pharmaceutical companies to develop new technologies for quickly diagnosing and treating fatal diseases.
Using autoantibody biomarker panels for improved disease diagnosis. By Dr John Anson, Oxford Gene Technology Winter 2011/12
In a new whitepaper, experts at Oxford Gene Technology (OGT) discuss the issues surrounding the detection and utilisation of novel biomarkers for disease diagnosis.
The Sooner the Better: Utilising biomarkers to eliminate drug candidates with cardiotoxicity in preclinical development. By Dr Federica Crivellente Summer 2011
The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early as possible in the drug development process. Today, only one in 11 compounds advance from first-in-man studies to regulatory approval and these late-stage failures mainly caused by safety issues exact a heavy toll on the biopharmaceutical industry as the cost of clinical trials is extremely expensive, legal liability is of concern and companies are under great scrutiny by investors
Early patient stratification is critical to enable effective and personalised drug discovery and development. By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf Summer 2011
With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5, we argue the need for personalised drug discovery and development to be executed at the beginning of the process and that the pharmaceutical industry's future successes will likely depend upon effectively enacting this paradigm.
The Personalized Medicine Coalition. Spring 2011
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients.
Genetics, Pipelines and Personalised Medicine. By Dr John W. Hooper Winter 2006
Genetic linkage studies have long been the standard for researching the genetics associated with heritable diseases. Recently, however, scientists have begun to realise the benefits of whole genome association studies, which enable them to view the entire human genome in greater detail.
The future of molecular diagnostics for cancer. By Dr Cliff Murray Drug Discovery Spring 2011
The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and predictive tests and speculate on where this area is heading with regard to advanced technologies and likely future requirements.
Page 1 to 16 of 32 | NEXT PAGE >